Phase II trial of pegylated liposomal doxorubicin (Caelyx™) plus Gemcitabine in chemotherapeutically pretreated patients with advanced breast cancer

References

• Bonadonna G, Vallagussa P, Moliterni A, Zambetti M, Brambilla C. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node positive breast cancer; the results of 20 years follow-up. New Engl J Med 1995; 14: 332–41
   Google Scholar
• Kaufmann M, von Minckwitz G, Smith R, Valero V, Gianni L, Eiermann W, et al. International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: Review and recommendations. J Clin Oncol 2003; 21: 2600–8
   PubMed Web of Science ®Google Scholar
• Valagussa P, Bonadonna G, Veronesi U. Patterns of relapse and survival following radical mastectomy. Cancer 1978; 41: 1170–2
   PubMed Web of Science ®Google Scholar
• Piccart MJ, Awada A. State-of-the-art chemotherapy for advanced breast cancer. Semin Oncol 2000; 27(Suppl 9)3–12
   PubMedGoogle Scholar
• Hudis CA. Current status and future directions in breast cancer therapy. Clin Breast Cancer 2003; 4(Suppl 2)S70–S75
   Google Scholar
• Fossati R, Confalonieri C, Torri V, Ghislandi E, Penna A, Pistotti V, et al. Cytotoxic and hormonal treatment for metastatic breast cancer: A systematic review of published randomized trials involving 31,510 women. J Clin Oncol 1998; 16: 3439–60
   PubMed Web of Science ®Google Scholar
• Geels P, Eisenhauer E, Bezjak A, Zee B, Day A. Palliative effect of chemotherapy: objective tumour response is associated with symptom improvement in patients with metastatic breast cancer. J Clin Oncol 2000; 18: 2395–405
   PubMed Web of Science ®Google Scholar
• Cardoso F, Leo AD, Lohrisch C, Bernard C, Ferreira F, Piccart MJ. Second and subsequent lines of chemotherapy for metastatic breast cancer: What did we learn in the last two decades?. Ann Oncol 2002; 13: 197–207
   PubMed Web of Science ®Google Scholar
• Symon Z, Peyser A, Tzemach D, Lyass O, Sucher E, Shezen E, et al. Selective delivery of doxorubicin to patients with breast carcinoma metastases by stealth liposomes. Cancer 1999; 86: 72–8
   PubMed Web of Science ®Google Scholar
• O'Shaughnessy JA. Pegylated liposomal doxorubicin in the treatment of breast cancer. Clin Breast Cancer 2003; 4: 318–28
   PubMedGoogle Scholar
• O'Brien MER, Wigler N, Inbar M, Rosso R, Grischke E, Santoro A, et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX™/Doxil®) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 2004; 15: 440–9
   PubMed Web of Science ®Google Scholar
• Hertel LW, Boder GB, Kroin JS, Rinzel SM, Poore GA, Todd GC, et al. Evaluation of the ant tumour activity of gemcitabine (2′,2′-difluoro-2′-deoxycytidine). Cancer Res 1990; 50: 4417–22
   PubMed Web of Science ®Google Scholar
• Heinemann V. Role of gemcitabine in the treatment of advanced and metastatic breast cancer. Oncology 2003; 64: 191–206
   PubMed Web of Science ®Google Scholar
• Carmichael J, Possinger K, Philip P, Beykirch M, Kerr H, Walling J, et al. Advanced breast cancer: A phase II trial with gemcitabine. J Clin Oncol 1995; 13: 2731–6
   PubMed Web of Science ®Google Scholar
• Spielmann M, Llombart-Cussac A, Kalla S, Espie M, Namer M, Ferrero JM, et al. Single-agent gemcitabine is active in previously treated metastatic breast cancer. Oncology 2001; 60: 303–7
   PubMed Web of Science ®Google Scholar
• Haider K, Kornek GV, Kwasny W, Weinländer G, Valencak J, Lang F, et al. Treatment of advanced breast cancer with gemcitabine and vinorelbine plus human granulocyte colony-stimulating factor. Breast Cancer Res Treat 1999; 55: 203–11
   PubMed Web of Science ®Google Scholar
• Jassem J. Gemcitabine and anthracyclines in breast cancer. Semin Oncol 2003; 30: 11–4
   PubMedGoogle Scholar
• Perez-Manga G, Lluch A, Alba E, Moreno-Nogueira JA, Palomero M, Garcia-Conde J, et al. Gemcitabine in combination with doxorubicin in advanced breast cancer: Final results of a phase II pharmacokinetic trial. J Clin Oncol 2000; 18: 2545–52
   PubMed Web of Science ®Google Scholar
• D'Agostino G, Ferrandina G, Ludovisi M, Testa A, Lo russo D, Gbaguidi N, et al. Phase II study of liposomal doxorubicin and gemcitabine in the salvage treatment of ovarian cancer. Brit J Cancer 2003; 89: 1180–4
   PubMed Web of Science ®Google Scholar
• Rivera E, Valero V, Syrewicz L, Rahman Z, Esteva FL, Theriault RL, et al. Phase I study of stealth liposomal doxorubicin in combination with gemcitabine in the treatment of patients with metastatic breast cancer. J Clin Oncol 2001; 19: 1716–22
   PubMed Web of Science ®Google Scholar
• Rivera E, Valero V, Arun B, Royce M, Adini R, Hoelzer K, et al. Phase II study of pegylated liposomal doxorubicin in combination with gemcitabine in the treatment of patients with metastatic breast cancer. J Clin Oncol 2003; 21: 3249–54
   PubMed Web of Science ®Google Scholar
• Miller AB, Hoogstraten B, Staquet M. Reporting results of cancer treatment. Cancer 1981; 147: 207–14
   Web of Science ®Google Scholar
• Gehan EA. The determination of the number of patients required in a follow-up trial of a new chemotherapeutic agent. J Chron Dis 1961; 13: 346–53
   PubMedGoogle Scholar
• Anderson JR, Bernstein L, Pike MC. Approximate confidence intervals for probabilities of survival and quantiles in life-table analysis. Biometrics 1982; 38: 407–16
   PubMed Web of Science ®Google Scholar
• Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 458–81
   Web of Science ®Google Scholar